PrimeRFP SCOUT · Federal Contract Recompete Brief

75N93022C00061NOVEL LPXC inhibitor WITH pan-resistant — Revagenix, Inc

Revagenix, Inc holds $32.8M across 2 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 1 related award in the incumbent pipeline. Competition previously drew 30 offers. Set-aside status: NONE. Recompete timing centers on the Apr 25, 2028 PoP end — agencies typically plan 12–18 months ahead.

National Institutes Of Health Niaid

Awarding office

Revagenix, Inc

Recipient

Apr 25, 2028

PoP end

$28.2M

Obligated

541715

NAICS

AN12

PSC

NONE

Set-aside

30 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Revagenix, Inc — $90

Contract facts

NONE

Contract number75N93022C00061

AgencyNational Institutes Of Health Niaid

Awarding officeNational Institutes Of Health Niaid

IncumbentRevagenix, Inc

UEID98QFZUPFXJ9

NAICS541715

PSCAN12

Place of performanceSAN MATEO, CA

Related solicitationPHS-2021-1

PoP end (current)Apr 25, 2028

Obligated$28.2M

A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. is a federal NONE award for National Institutes Of Health Niaid held by Revagenix, Inc. Estimated value $28.2M ($28.2M obligated). Current period of performance ends Apr 25, 2028. Last award drew 30 bidders. Place of performance: SAN MATEO, CA. Related solicitation PHS-2021-1.

A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY.

Recompete timing

Public

● Expiring in 596 days

Current PoP ends Apr 25, 2028 (596 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Oct 25, 2026.

Incumbent footprint

Public record

Revagenix, Inc — $32.8M obligated across 2 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$32.8M · 100% of firm total

Open full company profile →

Related awards

Same incumbent

75N93020C00018

EO14042 - TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE…

$26.9M

Oct 31, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N93022C00061?

75N93022C00061 (NOVEL LPXC inhibitor WITH pan-resistant) is a National Institutes Of Health Niaid award with an estimated value of $28.2M, currently held by Revagenix, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N93022C00061?

National Institutes Of Health Niaid awarded 75N93022C00061 to Revagenix, Inc.

Who is the incumbent on 75N93022C00061?

Revagenix, Inc is the incumbent with $32.8M across 2 related awards in SCOUT’s public footprint. The current period of performance ends Apr 25, 2028.

When does Revagenix, Inc’s 75N93022C00061 come up for recompete?

SCOUT tracks a period-of-performance end of Apr 25, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75N93022C00061 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Jul 10, 2026